A homozygous hypomorphic mutation in the deubiquitinase OTULIN causes a potentially fatal autoinflammatory disorder, which is reconciled in mouse models.
SUMMARY
Methionine-1 (M1)-linked ubiquitin chains regulate the activity of NF-kB, immune homeostasis, and responses to infection. The importance of negative regulators of M1-linked chains in vivo remains poorly understood. Here, we show that the M1-specific deubiquitinase OTULIN is essential for preventing TNFassociated systemic inflammation in humans and mice. A homozygous hypomorphic mutation in human OTULIN causes a potentially fatal autoinflammatory condition termed OTULIN-related autoinflammatory syndrome (ORAS). Four independent OTULIN mouse models reveal that OTULIN deficiency in immune cells results in cell-type-specific effects, ranging from over-production of inflammatory cytokines and autoimmunity due to accumulation of M1-linked polyubiquitin and spontaneous NF-kB activation in myeloid cells to downregulation of M1-polyubiquitin signaling by degradation of LUBAC in B and T cells. Remarkably, treatment with anti-TNF neutralizing antibodies ameliorates inflammation in ORAS patients and rescues mouse phenotypes. Hence, OTULIN is critical for restraining life-threatening spontaneous inflammation and maintaining immune homeostasis.
INTRODUCTION
Protein ubiquitination regulates virtually every aspect of cellular homeostasis, in large part through structurally and functionally distinct polyubiquitin (polyUb) signals (Komander and Rape, 2012) . PolyUb chains can be linked via one of seven Ub Lys (K) residues (e.g., K63-linked chains) or via Ub Met1 (M1), forming M1-linked (also known as linear) chains. The latter have important roles in regulating the immune system, in which they contribute to regulating nuclear factor-kB (NF-kB) transcription factors that orchestrate immune responses (Bonizzi and Karin, 2004) .
Ub chains regulate canonical NF-kB activation by mediating timed degradation of the inhibitor of kB (IkB) proteins but also serve as a scaffolding, recruitment, and activation platform in receptor signaling complexes. Non-degradative K63-and M1linked chains mediate the key upstream event of recruiting the TGFb-activated kinase (TAK1) and the IkB kinase (IKK) complexes, respectively (Jiang and Chen, 2012) . K63 and M1 linkages occur in the same Ub polymers (Emmerich et al., 2013) , facilitating TAK1 and IKK co-localization and cross-activation.
M1-linked chains are generated by the linear ubiquitin chain assembly complex (LUBAC) consisting of HOIP, HOIL-1, and SHARPIN Iwai et al., 2014) . LUBAC is recruited to many immune receptors, including TNF-R1, IL-1R, CD40, TLRs, and NOD2, in a Ub-dependent manner. At the receptors, LUBAC ubiquitinates a host of targets, including RIPK1, RIPK2, MyD88, IRAKs, and NEMO, directly or on pre-existing Ub chains Iwai et al., 2014) .
Genetic loss of LUBAC components leads to immunodeficiency (MacDuff et al., 2015) and inflammatory phenotypes in mice (Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga et al., 2011; 2009) , which can be rescued by co-deletion of TNF-R1 (Gerlach et al., 2011; Kumari et al., 2014; Peltzer et al., 2014; Rickard et al., 2014) . Mutations in LUBAC components also cause inflammatory conditions in humans . Hence, loss of M1-linked chains imbalances immune signaling.
Several deubiquitinating enzymes (DUBs), including A20, CYLD, and Cezanne, act as negative regulators of NF-kB signaling and are essential for resolving inflammation and the return to homeostasis (Harhaj and Dixit, 2012) . OTULIN (also known as FAM105B or Gumby) is the only DUB known to specifically cleave M1 linkages  Rivkin et al., (B and C) Lifetime measurements of (B) C-reactive protein (CRP) serum concentrations and (C) white blood cell (WBC, black line) and neutrophil numbers (cyan line) in blood from patients IV:3, IV:4, and V:2. Reference ranges (dotted lines) are indicated on the graphs. Patient V:2 was treated with Infliximab as indicated (orange shade). 2013) . OTULIN directly binds the LUBAC component HOIP, and knockdown of OTULIN in human cell lines increases M1-linked chains on LUBAC and its substrates (Elliott et al., 2014; Fiil et al., 2013; Rivkin et al., 2013; Schaeffer et al., 2014) . Strikingly, while LUBAC translocates to receptor signaling complexes (RSCs), OTULIN is not stably associated with TNF or NOD2 RSCs (Draber et al., 2015) , and how it regulates signaling complexes, e.g., TNF signaling, is unclear (Hrdinka et al., 2016) . Indeed, the physiological role of OTULIN in the immune system has remained unstudied, since OTULIN loss-of-function mutations lead to early embryonic lethality (E12.5-E14) in mice due to defective Wnt signaling and angiogenesis (Rivkin et al., 2013) .
Here, we describe that a homozygous hypomorphic OTULIN mutation in a consanguineous family causes a potentially fatal autoinflammatory disorder termed OTULIN-related autoinflammatory syndrome (ORAS), which can be managed by Infliximab (anti-TNF neutralizing antibody). We recapitulate key features of ORAS in mouse models of OTULIN deficiency. In an acute model, induced loss of OTULIN in immune cells leads to multiorgan inflammation and deterioration of animals within a few days; this can be ameliorated by anti-TNF, but not by neutralization of other upregulated cytokines. In addition, loss of OTULIN in myeloid cells generates a chronic model in which mice display increased serum levels of inflammation-associated cytokines and chemokines and develop splenomegaly and autoimmunity. In bone-marrow-derived macrophages (BMDMs), loss of OTULIN leads to overproduction of M1-linked Ub chains and dysregulated NF-kB activation and cytokine secretion. Strikingly, while mice lacking OTULIN in B or T cells do not display overt inflammatory phenotypes, further analysis indicates that these OTULIN-deficient cells have downregulated LUBAC components HOIP and SHARPIN, but not HOIL-1.
Together, the data from mouse models and human patients clearly establish OTULIN and M1-linked polyUb chains as key regulators of immune homeostasis, inflammation, and autoimmunity and reveal cell-type-specific effects of OTULIN in immune cells.
RESULTS

Hypomorphic OTULIN Germline Mutation in Patients with Idiopathic Inflammatory Disease
From the late 1990s, three premature newborns (born at week 34, week 36, and week 28+6, respectively) from a consanguineous family ( Figure 1A ) displayed severe idiopathic inflammatory symptoms. Within days to weeks after birth, they had repeated episodes of systemic inflammation with diarrhea and elevated serum C-reactive protein (CRP; Figure 1B ) and white blood cell (WBC) and neutrophil count ( Figure 1C ) without evidence of infection. All three eventually developed relapsing nodular panniculitis with neutrophil infiltrate and recurrent fevers. The patients showed reduced growth parameters and also exhibited painful swollen joints as well as elevated immunoglobulin levels and autoantibodies in serum (Table S1 and Experimental Models and Subject Details). Genetic testing excluded Mediterranean fever, chronic infantile neurological cutaneous articular syndrome, tumor necrosis factor-receptor associated periodic syndrome, and hyper IgD syndrome as the cause of the symptoms (Experimental Models and Subject Details).
SNP array analysis of the three affected individuals identified three regions of extended homozygosity at chromosomes 5 and 15 shared by all three individuals ( Figure S1A and Tables  S2 and S3 ). The largest region of shared homozygosity was at chromosome 5p15 from 13,802,063 to 16,722,976 bp between rs795541 and rs4702171. Genotyping of all available family members with microsatellite markers D5S817, D5S1991, D5S1992, D5S1963, and D5S416 confirmed linkage to this candidate region. Within the $3 Mb candidate region of chromosome 5p15, sequencing of FAM105A, FBXL7, MARCH11, ZNF622, and FAM34B revealed no candidate pathogenic variants. However, we detected a homozygous missense substitution in OTULIN/FAM105B in all affected individuals (c.815T>C; p.Leu272Pro) ( Figure 1D ). The parents of patient V:2 (IV:1 and IV:2) were both heterozygous for the substitution ( Figure 1D ), and none of the healthy siblings were homozygous for the c.815T>C variant (data not shown). Moreover, the variant was not present in the $12,000 and $120,000 alleles represented in the Exome Variant Server and EXaC datasets, respectively, either. Consistently, whole-exome sequencing of patient V:2 revealed no other homozygous or previously annotated pathogenic variants likely to cause the disease phenotype (Tables S2 and S3 ). Thus, we termed the described syndrome OTULIN-related autoinflammatory syndrome (ORAS) ( Figure 1E ).
Leu272 is located in a helix of the catalytic OTU domain that forms part of the binding pocket for M1-linked diUb, and mutation to Pro would be predicted to disrupt OTULIN Ub binding ( Figure 1F ). Recombinant OTULIN L272P displayed small differences in overall fold and reduced thermal stability (Figures S1B and S1C), and expression of OTULIN L272P in HEK293 cells consistently led to significantly reduced levels of OTULIN L272P as compared to wild-type protein ( Figure S1D ). OTULIN L272P , although less stable, maintained its interaction with HOIP ( Figure S1D ).
In addition to reduced stability, OTULIN L272P was 1,000-10,000 times less active toward M1-linked di-and tetraUb (Figures 1G and S1E) . M1-diUb binding to catalytically inactive OTULIN C129A/L272P was significantly diminished yet not completely abrogated ( Figure S1F ). OTULIN L272P was still M1-linkage (D) OTULIN DNA sequence chromatograms identifying the homozygous single-base substitution (c.815 T>C, p.Leu272Pro, arrowhead Figure S1 and Tables S1-S3. specific ( Figure S1G ), as the affected Ub binding site does not dictate OTULIN specificity .
Reduced stability and activity of OTULIN suggested an impact on M1-linked polyUb in ORAS patients. Patient blood samples confirmed the presence of OTULIN, albeit at slightly reduced levels as compared to control samples, as well as the presence of SHARPIN ( Figure 1H ). Strikingly, while samples from agematched controls showed barely detectable levels of M1-linked chains, this chain type was strongly increased in the ORAS patient sample.
We conclude that loss of OTULIN function and increased levels of M1-linked polyUb in human cells may indeed lead to the severe inflammation and autoimmunity observed in ORAS.
Neutralization of TNF Ameliorates Systemic
Inflammation in ORAS Importantly, ORAS can be managed by treatment with the anti-TNF antibody Infliximab. Treatment of affected patients with prednisolone (general corticosteroidal immunosuppressant), azathioprine, and methotrexate (anti-proliferative immunosuppressive drugs), as well as Anakinra (recombinant IL-1R-antagonist), had little or no effect on the symptoms ( Figure 1E and Experimental Models and Subject Details). Patient IV:3 died at 16 months of age of pneumococcal septicemia, and patient IV:4 died from an episode of systemic inflammation leading to acute renal failure and pulmonary edema at age 5. Of note, neither patient IV:3 nor IV:4 were treated with Infliximab. By contrast, patient V:2 responded well to treatment with Infliximab ( Figures 1B and 1C ) and is currently alive (age 11) with wellcontrolled disease. Infliximab treatment drastically reduced the symptoms, and serum levels of CRP as well as WBC and neutrophil counts in blood, returned to normal ranges after treatment ( Figures 1B, 1C ), suggesting a TNF-mediated pathogenesis in the patients.
Deletion of Otulin in Mouse Immune Cells Drives Acute Systemic Inflammation
To understand how OTULIN deficiency caused autoinflammation and autoimmunity, we attempted to recapitulate ORAS in mouse models. Due to embryonic lethality (Rivkin et al., 2013) , heterozygous Otulin +/LacZ mice (Figures S2A and S2B) were bred with appropriate inducible and/or tissue-specific Cre expressing mouse strains. OTULIN was expressed in several tissues in Otulin +/LacZ embryos and adult wild-type mice, including spleen and thymus (Figures S2C and S2D) . In immune cells, OTULIN was expressed in T cells, B cells, and natural killer (NK) cells and prominently in dendritic cells and macrophages (Figure 2A ).
We generated CreERT2-Otulin LacZ/flox mice, in which Otulin can be ablated in all cells with tamoxifen administration. Tamoxifen administration led to mice becoming moribund within a day (data not shown), suggesting strong phenotypes also in adult mice in addition to reported developmental defects (Rivkin et al., 2013) . This prevented further study, and to investigate the role of OTULIN in the immune system, we generated CreERT2-Otulin flox mixed bone marrow chimeras ( Figure 2B ), which were healthy (data not shown) and showed similar levels of CD45.1 + and CD45.2 + cells in vivo ( Figure S2E ).
Six to eight weeks after reconstitution, chimeric mice were treated with tamoxifen to induce Otulin ablation ( Figure S2F ). Strikingly, this resulted in rapid weight loss in CreERT2-Otulin LacZ/flox chimeras as compared to controls (Figures 2C and S2G) . Weight loss was accompanied by a pronounced increase in the number of circulating neutrophils in CreERT2-Otulin LacZ/flox chimeras ( Figure 2D ), while the number of lymphocytes and monocytes and the overall number of blood cells or splenocytes did not change (Figures 2D, S2E, and S2H) . We also observed a marked increase in the pro-inflammatory cytokines TNF and IL-6, the neutrophil cytokines G-CSF and KC, and the monocyte/macrophage chemokine MCP-1 in serum of CreERT2-Otulin LacZ/flox chimeras compared with CreERT2-Otulin +/flox chimeras and vehicle-treated controls (Figures 2E and 2F and Table S4 ). These cellular and molecular mediators are indicative of an inappropriate and damaging inflammatory response mediated by OTULIN-deficient myeloid cells. As expected in the short timeframe, cytokines associated with adaptive immunity were not elevated ( Figure 2E and Table S4 ).
Necropsy of the chimeras did not reveal any gross anatomical changes, but flow cytometry analysis showed substantial infiltration of CD11b + Gr-1 + neutrophils in the peritoneal lavage (PL), spleen, and liver and, to some extent, lung and kidney in CreERT2-Otulin LacZ/flox chimeras compared with CreERT2-Otulin +/flox or vehicle-treated controls ( Figures 2G, 2H , and S2I-S2L). Histological analysis confirmed immune cell infiltration in the livers of CreERT2-Otulin LacZ/flox chimeras with inflammatory foci scattered in the parenchyma (Figure 2I , arrowheads). With the exception of PL, where neutrophils were recovered in lower numbers after tamoxifen treatment, tissue-infiltrating Figure S2 and Table S4. neutrophils consisted of overall similar numbers of CD45.1 + wildtype cells and CD45.2 + OTULIN-deficient cells ( Figure S2M ). This suggests that loss of OTULIN does not cause aberrant cell death in immune cells ( Figure S2E ) and that the high levels of cytokines and chemokines present activate the entire immune cell population.
Collectively, this shows that deletion of Otulin in immune cells leads to spontaneous and severe acute systemic inflammation characterized by rapid weight loss, increased levels of pro-inflammatory cytokines (in particular, TNF, G-CSF, and IL-6) in serum, neutrophilia with all the hallmarks of emergency granulopoiesis (see Figures S3A-S3C ), and infiltration of neutrophils into multiple tissues. This highly pro-inflammatory phenotype of the OTULIN-deficient adult mice is unlikely to arise from defects in Wnt signaling during development (Rivkin et al., 2013) but indeed shows several of the cardinal symptoms of ORAS ( Figure 1E ).
Rescue of Systemic Inflammation in OTULIN-Deficient Mice
We next tested whether the strong ORAS-like phenotype can be reversed by antibody treatments, as observed in the human disease. It was unclear whether any of the upregulated cytokines were independently regulated by OTULIN/M1-linked chains. Hence, we tested whether neutralization of TNF, G-CSF, or IL-6 impacted on the weight loss and emergency granulopoiesis observed in CreERT2-Otulin LacZ/flox chimeric mice.
In accordance with the effective treatment of ORAS patients with Infliximab, we found that anti-TNF neutralizing antibodies, administered in parallel with tamoxifen-induced Otulin deletion, completely ameliorated weight loss ( Figure 3A ). While the numbers of blood neutrophils were still elevated ( Figure 3B ), infiltrating neutrophils in spleen and PL of CreERT2-Otulin LacZ/flox were reduced to a level comparable to isotype-treated CreERT2-Otulin +/flox controls ( Figure 3C ). In contrast, anti-G-CSF or anti-IL-6 were unable to rescue the phenotype fully. While anti-G-CSF treatment strongly reduced blood neutrophil count and infiltration, it failed to rescue weight loss and mice remained cachexic ( Figures 3D-3F ). Anti-IL-6 treatment had no impact on neutrophilia, but weight loss was partially rescued ( Figure 3G -3I). This differential amelioration extended to neutrophil production in the bone marrow, where anti-G-CSF, but not anti-IL-6, reduced the number of uncommitted blood cells (''LSK'' cells, for Lin À Sca1 + c-Kit + cells) and immature neutro-phils to levels observed in isotype-treated controls ( Figures  S3D-S3F ). This confirms that G-CSF drives emergency granulopoiesis in CreERT2-Otulin LacZ/flox chimeras and may contribute to the neutrophilia observed in ORAS patients ( Figure 1D ). Strikingly, anti-TNF treatment of CreERT2-Otulin LacZ/flox chimeras resulted in a global reduction of cytokines, including G-CSF, KC, and TNF itself. IL-6 was reduced to background levels (Figures 3J and S3G) . Anti-G-CSF did not affect TNF or IL-6 levels and, in fact, caused elevated production of KC and G-CSF itself (although its functional blockade ameliorated neutrophilia) (Figures 3J and S3H) . Anti-IL-6 increased MCP-1 levels, possibly indicating a pathway for compensation in the absence of IL-6 ( Figures 3J and S3I ).
Together, these data implicate TNF as the pre-eminent factor in driving inflammation in OTULIN-deficient mice, although other cytokines and chemokines clearly contribute to the composite phenotype ( Figure 3K ). This finding correlates with the fact that anti-TNF treatment reverses the inflammatory symptoms in the ORAS patient and therefore suggests that OTULIN-deficient mice provide a good model to understand the mechanisms underlying ORAS.
Differential Effects of OTULIN Deletion in Cells of the Immune System
To dissect immune mechanisms contributing to the strong OTULIN deficiency phenotype, we employed mouse models in which Otulin can be constitutively ablated in specific immune cell lineages, namely T cells (''CD4Cre'' mice, expressing Cre recombinase under control of the Cd4 promoter), B cells (''MB1Cre'' mice, expressing Cre under control of the Mb1 promoter), and myeloid cells (''LysMCre'' mice, expressing Cre under control of the LysM promoter, leading to knockout in macrophages, neutrophils, and some dendritic cells).
Surprisingly, loss of OTULIN in T cells or B cells generated healthy mice with no overt inflammatory phenotypes, as assessed by phenotypic, blood cell, cytokine, and serum IgG analysis . Closer inspection of the B cell subsets in the MB1Cre-Otulin LacZ/flox mice indicated a trend toward lower B1 cell numbers but did not reach statistical significance ( Figure S4C ).
In stark contrast, deletion of OTULIN in myeloid cells resulted in a strong inflammatory phenotype. LysMCre-Otulin LacZ/flox mice were born at Mendelian ratios, appeared healthy at weaning, and showed similar survival as compared to controls but (legend continued on next page) were slightly smaller in terms of body weight (Figures S4D and S4E) . Indeed, closer inspection of 3-to 9-month-old LysMCre-Otulin LacZ/flox mice revealed a marked increase in the size of lymphoid organs and liver ( Figures 4E and S4F ) and prominent leukocytosis with increased numbers of circulating neutrophils, lymphocytes, and monocytes (Figures 4F) as compared to controls.
Deletion of Otulin in Myeloid Cells Leads to Chronic Inflammation and Autoimmunity
Strikingly, serum analysis showed that 16 out of 25 tested cytokines and chemokines were markedly elevated in LysMCre-Otulin LacZ/flox mice (Figures 4G and 4H and Table S7 ), including the pro-inflammatory cytokines TNF, IL-6, and IL-1b; the neutrophil and monocyte attractants/activators MCP-1 and MIP-1a; and G-CSF. Interestingly, cytokines associated with T cell activation and adaptive immunity, such as IL-2, IL-4, IFNg, and RANTES, were also elevated (Figures 4G and 4H and Table  S7 ), as were serum IgG levels ( Figure 4I ). Collectively, these findings indicate ongoing, systemic inflammation in LysMCre-Otulin LacZ/flox mice involving both innate and adaptive immune cells.
Histological analysis revealed substantial immune cell infiltration in livers of LysMCre-Otulin LacZ/flox mice, particularly around veins but also in the parenchyma, and a distorted splenic architecture ( Figures 5A and 5B ). Collagen deposits in liver ( Figure 5A , right) and spleen ( Figure 5B , right) were visible and consistent with chronic inflammation. Moreover, germinal center activation was evident in LysMCre-Otulin LacZ/flox spleens ( Figure 5B , left), suggesting B cell hyperactivation and potential for immunoglobulin-mediated pathology. Flow cytometric analysis showed that LysMCre-Otulin LacZ/flox mice had greater numbers of both CD11b + Gr-1 + neutrophils and CD11b + Gr-1 À macrophages in PL, spleen, liver, lungs, and kidney compared with LysMCre-Otulin +/flox mice ( Figures 5C, 5D , S5A, and S5B). LysMCre-Otulin LacZ/flox mice also had increased numbers of CD8 + T cells in liver and kidney (Figures 5D, S5C, and S5D), consistent with systemic chronic inflammation and involvement of the adaptive immune system. The number of CD4 + T cells remained normal (data not shown).
High-serum IgG and the appearance of active germinal centers in LysMCre-Otulin LacZ/flox mice suggested B cell hyperactivation, leading to higher levels of antibodies in the serum, a hallmark of autoimmunity. Indeed, the amounts of serum immunoglobulin isotypes IgG1, IgG2a and b, IgA, and IgM were elevated in LysMCre-Otulin LacZ/flox serum, while IgG3 levels were unchanged when compared to LysMCre-Otulin +/flox (Figure 5E ). This indicated polyclonal B cell activation and suggested that LysMCre-Otulin LacZ/flox mice could be autoimmune. Consistent with this, ELISA analysis revealed higher antibody reactivity against extractable nuclear antigens (ENA), double-stranded DNA (dsDNA), and Smith antigen in LysMCre-Otulin LacZ/flox serum ( Figure 5F ). B cell activating factor (BAFF) is the primary cytokine that governs peripheral B cell tolerance, and increased BAFF levels can lead to T-cell-independent B cell activation and immunoglobulin production (Groom et al., 2007) . Indeed, we found that LysMCre-Otulin LacZ/flox mice had elevated levels of BAFF in serum ( Figure 5G ), suggesting that secretion of BAFF resulting from OTULIN deficiency leads to breakdown of peripheral tolerance and activation of autoreactive B cells.
Collectively, these results show that OTULIN is essential in myeloid cells to prevent unwarranted secretion of cytokines leading to inflammation, as well as autoimmunity ( Figure 3K ).
OTULIN Deficiency Leads to Sterile Autoactivation of Inflammatory Pathways
We next investigated the molecular mechanisms resulting in the strong inflammatory phenotypes, using BMDMs from LysMCre-Otulin +/flox , LysMCre-Otulin LacZ/flox , or LysMCre-Otulin del/flox mice, which were cultured and studied for pathway activation by western blotting in the absence of any exogenous stimulation. Interestingly, in agreement with the patient samples, the levels of M1-linked Ub chains were markedly increased ($8-fold on average) in OTULIN-deficient BMDMs, in particular in the highmolecular-weight range, while K63-linked, K48-linked, or total Ub levels were unchanged ( Figure 6A ). Strikingly, this resulted in NF-kB activation evidenced by degradation of IkBa and increased phosphorylation of p65/RelA in the absence of exogenous stimuli ( Figure 6B ). Cycloheximide chase experiments confirmed the increased turnover of IkBa ( Figure 6C ), a hallmark of NF-kB pathway activation. This correlated with increased transcription of NF-kB target genes such as Tnf, Nfkbia (IkBa), Il6, and Tnfaip3 (A20) ( Figure 6D ) and concomitant secretion of TNF and IL-6 ( Figure 6E ). Also, LysMCre-Otulin +/flox and LysM-Cre-Otulin LacZ/flox BMDMs were similarly viable when left untreated or when treated with LPS, TNF, or Staurosporine ( Figure 6F ), suggesting no apparent sensitization to cell death in these cells.
Importantly, while SHARPIN levels were slightly reduced, the levels of HOIP and HOIL-1 were unchanged in LysMCre-Otulin LacZ/flox BMDMs ( Figure 6G ), consistent with strong production of M1-linked polyUb in these cells ( Figure 6A ). Protein levels of NEMO/IKKg, A20, and CYLD were similar to controls ( Figure 6G ). LUBAC signaling may impact alternative inflammatory pathways, yet in LysMCre-Otulin del/flox BMDMs, NF-kBinducing kinase (NIK) was not stabilized (indicating no activation of non-canonical NF-kB), and IRF-3 or p38 phosphorylation was not increased (suggesting that IRF or MAPK signaling pathways were not active) ( Figure 6H ).
Finally, we examined the response of BMDMs to TNF. Since these cells secrete TNF ( Figure 6E Data are presented as mean ± SEM, and n represents number of mice. See also Figure S4 and Tables S5-S7. response may, in part, originate from autocrine signaling. Indeed, when MEFs were treated with anti-TNF antibodies, exogenous TNF was unable to induce IkBa degradation and p65 phosphorylation ( Figure S6A ). Importantly, when TNF was neutralized in the culture medium of untreated BMDMs, IkBa levels decreased with similar kinetics as compared to isotypetreated BMDMs ( Figure 6C , quantified in Figure 6I ). This provided further strong evidence for a cell-autonomous activation of NF-kB in OTULIN-deficient BMDMs.
Autocrine signaling would be further enhanced in a positive feedback mechanism if loss of OTULIN would strengthen the response to TNF. Indeed, stimulation of BMDMs with TNF led to stronger transcriptional upregulation of Tnf in cells from LysMCre-Otulin del/flox ( Figure 6J ), consistent with a role of OTULIN as a negative regulator in this pathway.
Together, this shows that OTULIN-deficient macrophages are unable to control LUBAC-mediated production of M1-linked polyUb chains and that this signal leads to stimulus-independent basal NF-kB activation and ''sterile'' inflammatory signaling, possibly enhanced by autocrine feedback. The idea of sterile inflammation is further supported in CreERT2-Otulin LacZ/flox chimeras that have been treated with broad-spectrum antibiotics to reduce the microbial load; these mice display an identical inflammatory phenotype as compared to untreated CreERT2- Figure 2 ).
Cell-Type-Specific Differences in Response to OTULIN Deficiency
While loss of OTULIN from myeloid cells and the concomitant dysregulation of M1-linked polyUb resulted in a profound inflammatory phenotype, this was not evident in mice lacking OTULIN in B or T cells ( Figure 4 ). This is surprising since M1 signaling has recently been implicated in T cell signaling (Park et al., 2016; Redecke et al., 2016) and B cell signaling (Sasaki et al., 2013; Satpathy et al., 2015; Yang et al., 2016) . The DUB-regulating M1-linked polyUb in B and T cells has not been elucidated.
To understand this, the M1-Ub signaling cascade was characterized in purified T and B cells from respective knockout mice. To our great surprise, this revealed an almost complete loss of LUBAC components HOIP and SHARPIN, but not HOIL-1, in either of the two independent models ( Figures 7A and 7B ). As discussed above, LysMCre-Otulin LacZ/flox BMDMs showed mildly reduced SHARPIN levels but no difference in HOIP levels.
Further evaluation of myeloid cells purified from various tissues likewise showed no loss of HOIP or HOIL-1 and only marginally reduced SHARPIN levels ( Figure 7C ). Such tissue-and subunit-specific regulation of LUBAC components has not been observed previously.
We next investigated the mechanism of OTULIN-dependent LUBAC regulation. Transcription of HOIP (Rnf31), SHARPIN (Sharpin), and HOIL-1 (Rbck1) genes was unaltered in CD4Cre-Otulin del/flox T cells and MB1Cre-Otulin LacZ/flox B cells (Figures 7D and 7E) . In contrast, SHARPIN (but not HOIP) levels were partially rescued in purified T and B cells after MG132 treatment, indicating that loss of SHARPIN is due to proteasomal degradation ( Figures 7F and 7G ). This reveals a role for OTULIN in the stabilization of LUBAC components that warrants further investigation.
DISCUSSION
We provide genetic evidence that OTULIN is a crucial in vivo regulator of inflammation in mice and humans, identify TNF as a key driver of the phenotypes caused by OTULIN deficiency, and show that OTULIN deficiency and ORAS can be treated with anti-TNF/Infliximab in mice and humans.
The discovery of an OTULIN mutation in human patients with a severe inflammatory syndrome, ORAS, highlights how deregulation of a single Ub chain signal, M1-linked polyUb, causes human disease. Mutations of LUBAC components are also associated with inflammatory syndromes (Boisson et al., 2012 , yet these constitute loss-of-function mutations with regards to M1-polyUb signaling. In contrast, loss of function of OTULIN leads to an amplification of the M1-polyUb signal ( Figure 1H) . Strikingly, the net result, inflammation, is the same, highlighting how the essential M1-polyUb signal is delicately balanced to determine a cellular output.
Many DUBs have been identified to play key roles in regulating signaling pathways; however, we are unaware of another enzyme that, when removed from cells, has such global effects on a single chain type. The marked upregulation of M1-linked chains in OTULIN-deficient BMDMs and ORAS patient samples suggests that there is little redundancy for regulation of this chain type. Two recent reports implicate CYLD in the regulation of M1-polyUb signaling at receptor complexes (Draber et al., 2015; Hrdinka et al., 2016) . Quantitative mass spectrometry analysis showed that OTULIN is not present at TNF and NOD2 RSCs, but while one group suggests that OTULIN's role is restricted to LUBAC homeostasis (Draber et al., 2015) , our work suggests that, while OTULIN might not stably associate with the receptor complexes, it plays active roles in receptor signaling (Hrdinka et al., 2016 ) (see above, Figure 6J) .
Physiologically, our data support a model whereby the unrestricted accumulation of M1-linked Ub chains leads to sterile inflammation due to stimulation-independent activation of NF-kB ( Figure 7H) . Importantly, the role of OTULIN in NF-kB inhibition is conceptually distinct from other NF-kB-induced negative feedback regulators, such as A20 (Harhaj and Dixit, 2012) . OTULIN is not under transcriptional control by NF-kB (Fiil et al., 2013; but appears to constitutively and efficiently remove M1-linked polyUb signals. In the absence of OTULIN, LUBAC activity is unrestricted, and such signals accumulate in a deregulated fashion to initiate uncoordinated NF-kB activation and sterile inflammation. The downstream effects of this include secretion of pro-inflammatory cytokines, immune cell activation, and infiltration, culminating in severe inflammatory phenotypes ( Figures 3K and 7H) .
Strikingly, this is not always the case. Mice with OTULIN deficiency in B or T cells do not show overt phenotypes, and this is due to downregulation of LUBAC components HOIP and SHARPIN, but not HOIL-1, at the protein level, in OTULIN-deficient cells ( Figures 7A, 7B, 7H ). Genetic loss of SHARPIN in cpdm mice destabilizes both HOIP and HOIL-1 (Gerlach et al., 2011; Ikeda et al., 2011; Tokunaga et al., 2011) , contrasting the stability of HOIL-1 in our models. This may point to differentiated use of LUBAC components in immune cells. Second, OTULIN only cleaves non-degradative M1-linked polyUb. Knockdown of OTULIN leads to M1 polyubiquitination of all three LUBAC components (Fiil et al., 2013; Hrdinka et al., 2016) . It is possible that these chains, at least on HOIP and SHARPIN, are extended or edited in T and B cells by an unidentified E3 ligase to turn a non-degradative into a degradative signal. The mechanism of OTULIN-regulated LUBAC degradation requires further study, but the findings clearly suggest that whole-body OTULIN deficiency generates a complex composite phenotype, signified by cell-type-specific regulation of M1 signaling.
There are also subtle but important differences in the observed inflammatory phenotypes comparing CreERT2-Otulin LacZ/flox chimeras and LysMCre-Otulin LacZ/flox mice, which present differently in terms of severity of symptoms of disease, e.g., cachexia/ weight loss. The nearly identical absolute levels of serum TNF, the key mediator of the inflammatory phenotype (Figures 1  and 3) indicates that myeloid cells are responsible for TNF production, but this does not explain the phenotypic difference. Rescue experiments suggest that G-CSF regulates emergency granulopoiesis, but not cachexia. Instead, we uncover a prominent role of IL-6, a key mediator of TNF-and inflammationinduced cachexia (Morley et al., 2006) . This cytokine is higher in CreERT2-Otulin LacZ/flox chimeras as compared to LysMCre-Otulin LacZ/flox mice ( Figures 2F and 4H) , explaining, in part, the difference in the severity of phenotypes. Further differences include the temporal profile, with the chimera model being an induced, acute model and the myeloid-specific knockout being a constitutive, lifetime model. Finally, the numerous other upregulated cytokines in LysMCre-Otulin LacZ/flox mice, which includes anti-inflammatory IL-10, will generate a delicate balance of responses, enabling these mice to deal with inflammation induced by loss of OTULIN.
We show that excess M1-linked polyUb in cells of the immune system is harmful, but it most likely also affects other cell types and organs. For example, ORAS patients suffer from panniculitis, and it will be informative to study the role of OTULIN in skin homeostasis and inflammation. Moreover, the roles of OTULIN in embryonic development, potentially due to effects in the Wnt signaling pathway (Rivkin et al., 2013) , require further investigation. Our immune-specific mouse models are not suitable to investigate this in detail. Significantly, the fact that the heredescribed OTULIN-related autoinflammatory syndrome/ORAS can be treated with TNF-neutralizing antibodies suggests a potential therapeutic strategy to treat conditions caused by excessive M1-linked polyUb signaling.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Figure 1 and Tables S1, S2, and S3  Patient IV:3 The consultand is the first child born to consanguineous parents (III:3 and III:4) ( Figure 1A) at 34 weeks gestation via normal vaginal delivery and was small for gestational age. She presented at 3 weeks of age with protracted diarrhea and failure to thrive. She required total parenteral nutrition (TPN) and later nasogastric tube feeds. During her lengthy admission she was noted to have recurrent episodes of a widespread nodular erythematous rash associated with fever, elevated white blood cell count, neutrophilia, raised C-reactive protein (CRP) ( Figures 1B-D) , and an exacerbation of her diarrhea. An initial skin biopsy, taken as the rash was resolving, showed non-specific changes. Duodenal biopsies showed microvillous dystrophy. She also had mild hepatomegaly. A liver biopsy showed TPN-associated liver disease with micronodular cirrhosis and macrovisicular steatosis. Liver function later returned to normal, although hepatomegaly and the permanent damage from cirrhosis persisted. There are no records of splenomegaly in this patient. Echocardiogram identified an atrial septal defect.
The patient was extensively investigated to identify the cause of her protracted diarrhea and episodic skin rash including a number of immunological investigations. Of note she had normal alpha 1 anti-trypsin level, normal functional antibodies, normal lymphocyte subsets although with a modest increase in CD19 + B cells (2120 cells/mm 3 ; normal 500-1500), normal lymphocyte function tests, neutrophil function test, and normal NBT tests. She did have elevated IgG, IgM, and IgA levels (Table S1 ), raised CRP ( Figure 1C ), elevated C1q (171 mg/L; normal 80-150 mg/L) and C3 (2.75 g/L; normal 0.75-1.75 g/L), and she was positive for anti-neutrophil cytoplasmic antibody (ANCA) and anti-smooth muscle antibody (SMA), both 1:100 titers. When she was treated with intravenous methylprednisolone, her fever, diarrhea, and rash would resolve, but these clinical features would return when attempts were made to change to oral prednisolone. Azathioprine and methotrexate were also trialed. In a course of 3 months she had three cases of severe bilateral pneumonia progressing to sepsis and renal tubular necrosis, hematuria, proteinuria, and raised urea and creatinine requiring admittance to the pediatric intensive care unit. She survived two episodes, but sadly died at 16 months during the third episode of pneumococcal septicemia, which led to respiratory collapse.
Patient IV:4
The consultand is the second child born to consanguineous parents (III:3 and III:4) ( Figure 1A) at 36 weeks gestation via normal vaginal delivery with a birth weight of 2 kg. She was diagnosed with relapsing nodular panniculitis at 3 days of age. A skin biopsy showed no evidence of vasculitis. This rash, similarly to her sister (patient IV:3) and cousin (patient V:2), was episodic and associated with diarrhea (bloody at presentation), vomiting, fever, and painful swollen joints and difficulty sleeping. She had elevated white blood cell counts with pronounced neutrophilia as well as raised CRP levels ( Figures 1B-D) , as well as elevated C3 (2.77 g/L; normal 0.75-1.75 g/L), but was negative for ANCA autoantibodies (she was not tested for other autoantibodies). She had normal lymphocyte subsets. There are no records of hepatosplenomegaly in this patient. She required nasogastric tube feeds for failure to thrive. All growth parameters were below the 0.4th centile. She also had bilateral cataracts diagnosed at the age of 5 months and developmental delay. The cataracts were not present in the neonatal period on formal ophthalmological examination and were not secondary to steroid use.
She was treated with prednisolone from the age of 1 month, and with azathioprine and Anakinra (recombinant IL-1R-antagonist) unsuccessfully. She had recurrent urinary tract infections and viral illnesses, which coincided with immunosuppressive therapy. During a severe episode of inflammation at the age of five she demonstrated features consistent with a high cell turnover including elevated potassium, phosphate, uric acid, LDH, elevated white blood cell count and a metabolic acidosis. She was admitted to pediatric intensive care with acute renal failure, pulmonary edema and an ileus, but sadly passed away just before turning 5 years old. Treatment had included intubation and ventilation, intravenous methylprednisolone, dexamethasone, and methotrexate. In this patient, Familial Mediterranean Fever, Chronic Infantile Neurological Cutaneous Articular syndrome, Tumor necrosis factor Receptor-Associated Periodic Syndrome, and Hyper IgD syndrome had all been excluded by genetic analysis.
Patient V:2
The consultand is the second child born prematurely at 28+6 weeks gestation to consanguineous parents (IV:1 and IV:2) ( Figure 1A ) with a birth weight of 1.23 kg. He developed relapsing nodular panniculitis at 8 weeks of age while he was in the neonatal intensive care unit. Prior to the appearance of his skin rash, he had repeated episodes of possible infection with raised CRP levels and elevated white blood cell count and neutrophilia ( Figures 1B-D) , but no focus of infection could be identified. The rash was biopsied and this confirmed inflammation in the dermis extending into the subcutaneous layer with a mixed inflammatory cell infiltrate. No granulomas or vasculitis was seen. He has had frequent flare-ups involving widespread painful lumps in the skin lasting 2 days to 2 weeks. During these episodes he was systemically unwell with fever, vomiting, diarrhea (sometimes bloody), inflamed painful joints, swollen feet, and weight loss associated with elevated CRP levels and white blood cell count ( Figures 1C and 1D) , with a neutrophilia showing toxic granulation and a left shift. He would lose his appetite, lose weight, and become dehydrated, which required admission to the high dependency unit on some occasions. These episodes appeared to resolve with an increase in the dose of prednisolone. In addition, he seemed susceptible to frequent infections especially viral illnesses including varicella zoster virus (VZV), influenza A, respiratory syncytial virus (RSV), adenovirus, and cytomegalovirus (CMV), although these coincided with immunosuppressive therapy. He had poor weight gain, slow linear growth, developmental delay, mild learning difficulties, congenital hydroceles, dental caries, a pathological osteoporotic tibial fracture and he developed juvenile cortical cataracts at 2-3 years of age, which were treated with a bilateral lensectomy and vitrectomy. There are no records of hepatosplenomegaly in this patient.
On examination, his growth parameters were all less than the 0.4th centile. He had a prominent nodular rash in keeping with a flare of panniculitis. He had coarse hair with bushy eyebrows, slight hyper-telorism, broad nasal bridge, prominent nose, protruding normally formed ears and a prominent chin.
He had comprehensive immunological investigations which were normal including lymphocyte subset panel and proliferation analysis, a normal neutrophil oxidative burst, and normal expression of CD11a,b,c, CD18, CD55, CD95, MHCI, MHCII, and CD25. He had increased IgA and IgM levels (Table S1) in serum and a single strongly positive anti-smooth muscle antibody (SMA; 1:320 titer), but no other autoantibodies. He does not have alpha-1 antitrypsin deficiency or pancreatitis. The most recent skin biopsy demonstrated inflammatory infiltrates composed of lymphocytes and neutrophils within the subcutis, associated with foci of fat necrosis where neutrophils are particularly prominent. The inflammation seemed predominantly septal, but with extension into the lobules. Some of the septal blood vessels showed edema of their walls, but no frank vasculitis was identified. The features were very similar to those seen in the biopsy from his cousin (patient IV:4) and suggested a neutrophil-rich panniculitis with fat necrosis favoring septal distribution.
He has been treated both with systemic steroids and Anakinra (recombinant IL-1R-antagonist). Neither medication successfully prevented the exacerbations or additional symptoms. Infliximab (TNF neutralizing antibody) was introduced eight years ago (at age $3) and has successfully controlled the disease. He has had a couple of minor exacerbations when the frequency of the Infliximab treatments was decreased, or the dose per kg fell to nearly 5 mg/kg. In addition to this, he takes prophylactic methotrexate, azithromycin, and aciclovir.
Mice
All animal experiments were undertaken with the approval of the UK Home Office. All mice were on a C57BL/6 or B6.SJL background and maintained under specific pathogen-free conditions in individually ventilated cages (Techniplast GM500, Techniplast) on Lignocel FS14 spruce bedding (IPS, Ltd.) with environmental enrichment (fun tunnel, chew stick, and Enviro-Dri nesting material (LBS)) at 19-23 C with light from 7.00 a.m. to 7.00 p.m. and fed Dietex CRM pellets (Special Diet Services) ad libitum.
Otulin/Fam105b-targeted JM8A3.N1 (C57BL/6 background strain) ES cells (Fam105b tm1a(EUCOMM)Hmgu ) were obtained from EUCOMM and used to generate mice bearing neomycin selection and LacZ cassettes and a loxP-flanked exon 3 of Otulin, termed the targeted ''LacZ '' or ''LZ'' (figures) allele (see also Figure S1 ). Heterozygous Otulin +/LacZ mice were normal and asymptomatic (data not shown), but intercrossing of Otulin +/LacZ mice failed to generate viable Otulin LacZ/LacZ offspring, consistent with previous work (Bonizzi and Karin, 2004; Rivkin et al., 2013) . The neomycin selection and LacZ cassettes were removed from the targeted allele by intercrossing with FLPe-recombinase expressing mice (Rodríguez et al., 2000) to generate the conditional, floxed allele, which can be conditionally ablated by the Cre recombinase leading to a frameshift and a premature stop codon (p.Glu77Glyfs*Ter3) ( Figures  S2A and S2B) , and the Otulin flox strain (Otulin +/flox and Otulin LacZ/flox mice). Otulin flox mice were bred with Rosa26-Cre-ERT2 (Hameyer et al., 2007 ) (CreERT2-Otulin flox ), LysM-Cre (Clausen et al., 1999 ) (LysMCre-Otulin flox ), CD4-Cre (Lee et al., 2001 ) (CD4Cre-Otulin flox ), and Mb1-Cre (Hobeika et al., 2006 ) (MB1Cre-Otulin flox ) mice to facilitate conditional deletion of Otulin. Pilot experiments showed that CreERT2-Otulin LacZ/flox mice reacted adversely to tamoxifen administration, becoming moribund within a day of Otulin deletion (data not shown).
In individual experiments, mice were matched for age and background strain. All experiments, except for embryo staining (see below) were performed on adult mice. For ERT2Cre-Otulin flox bone marrow chimeric mice, recipient mice were 2-3 months old and in each experiment were either all male or all female. No differences in results were observed between experiments performed on male and female mice. For LysMCre-Otulin flox , CD4Cre-Otulin flox , MB1Cre-Otulin flox mice, experiments were performed with a mix of male and female mice in experimental groups. LysMCre-Otulin flox , CD4Cre-Otulin flox , MB1Cre-Otulin flox mice used in experiments were 2-9 months old. Mice were allocated to experimental groups based on genotype. Grouping of mice into cages was determined at weaning, but where possible animals of equivalent age and gender were allocated to each experimental group. Where multiple groups of the same genotype were required, these were allocated randomly to the particular treatment conditions. Sample sizes were estimated using pilot experiments.
Bone Marrow-Derived Macrophages
Bone marrow-derived macrophages (BMDMs) were generated from bone marrow cells derived from tibias, femurs, and pelvic bones from LysMCre-Otulin +/flox , LysMCre-Otulin LacZ/flox or LysMCre-Otulin del/flox mice. Bones were flushed in PBS supplemented with 3% (v/v) FCS and cells were cultured and differentiated in RPMI 1640 + GlutaMAX supplemented with 10% (v/v) FCS, Penicillin/Streptomycin, 5 mM b-mercapto ethanol, nonessential amino acids (GIBCO), and 20 ng/mL recombinant mouse M-CSF (R&D Systems, Minneapolis, MN) as described previously (Damgaard et al., 2012) . BMDMs denoted 'untreated' in experiments indicates no exogenous stimulation of these cells after differentiation.
Cell Lines HEK293 cells and mouse embryonic fibroblasts (MEFs) were cultured in DMEM + GlutaMAX supplemented with 10% (v/v) FCS and Penicillin/Streptomycin at 37 C in a humidified atmosphere at 5% CO 2 unless otherwise indicated in figure legends or method details.
METHOD DETAILS
Molecular Genetic Analysis
Blood genomic DNA was isolated using the DNeasy kit (QIAGEN). A genome-wide linkage scan was carried out using the Affymetrix 250K SNP microarray with DNA from the three affected patients (V:2, IV:3 and IV:4). Homozygous regions were identified in affected patients using the program HomozygosityMapper (http://www.homozygositymapper.org/) (Seelow et al., 2009 ) and further analyzed to confirm or refute linkage by typing microsatellite markers in all family members from whom DNA was available. Direct sequencing of the genes within the identified region was prioritised according to putative function and position. The genomic DNA sequence of candidate genes was taken from Ensembl (http://www.ensembl.org/index.html) and primer pairs for the translated exons were designed using ExonPrimer software (https://ihg.gsf.de/ihg/ExonPrimer.html). Individual exons and flanking sequences were amplified using standard polymerase chain reaction (PCR) (primer details and conditions on request). PCR products were directly sequenced by the Big Dye Terminator Cycle Sequencing kit and run on an ABI PRISM 3730 DNA Analyzer (Applied Biosystem). Sanger sequencing was repeated on at least two independent PCR products to confirm sequence variants. DNA sequences were analyzed using the Chromas software (Technelysium). Whole Exome Sequencing was performed as described previously (Clark et al., 2014) . Exon capture was performed with the SureSelect All Exon 50Mb Target Enrichment System (Agilent) and massively parallel DNA sequencing was undertaken on an Illumina AnalyserIIx with 76bp paired end reads. Single nucleotide substitutions and small insertion deletions were detected and quality filtered within the SamTools software package (http://samtools.sourceforge.net/) (Li et al., 2009 ) and in-house software tools. Variants were annotated with the Annovar tool (http://wannovar.usc.edu/index.php) (Yang and Wang, 2015) . Filtering of variants for novelty was performed by comparison to dbSNP132 and 1000 Genomes SNP calls (June 2011) and patient variants were compared to variants identified in 250 control exomes sequenced and analyzed in a similar manner. The Exome Variant Server (http://evs.gs.washington.edu/EVS/) and the EXaC Browser (http://exac.broadinstitute.org/gene/ ENSG00000154124) datasets were accessed October 2015.
b-Galactosidase Staining of Mouse Embryos E13.5 Otulin +/LacZ and Otulin +/+ embryos were dissected from the uterine tracts and immediately transferred to ice cold 4% PFA in PBS and left to fix for 1 hr. Fixed embryos were washed in rinse buffer (5 mM EGTA, 0.01% (w/v) deoxycholate, 0.02% NP-40 (v/v), 2 mM MgCl 2 in PBS) and transferred to staining buffer (5 mM K 3 [Fe(CN) 6 ], 5 mM K 4 [Fe(CN) 6 ], 5 mM EGTA, 0.01% deoxycholate (w/v), 0.02% NP-40 (v/v), 2 mM MgCl 2 , 1 mg/mL 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal) in PBS) and left to incubate 24 hr in the dark at 37 C. After staining, embryos were washed in rinse buffer and post-fixed in 4% PFA in PBS for 48 hr at room temperature. Embryos were then washed in PBS and dehydrated by sequential washes in increasing concentrations of ethanol ending with 100% ethanol for 30 min and then cleared in methyl salicylate (Sigma Aldrich) for 30 min. Embryos were allocated to experimental groups based on genotype. This experiment was performed on embryos from two independent litters, and a total of five Otulin +/+ and five Otulin +/LacZ embryos were analyzed.
Mixed Bone Marrow Chimeras
One week before transplantation, the drinking water of recipient mice was supplemented with 0.1 mg/mL enrofloxacin (Baytrilâ, Bayer). Bone marrow cells (2 3 10 6 ) from wild-type CD45.1 + B6/SJL mice and CD45.2 + CreERT2-Otulin +/flox or CreERT2-Otulin LacZ/flox mice were resuspended in 100 mL PBS at a 1:1 ratio and then injected intravenously (i.v.) into 2-3 months old sex-and age-matched g-irradiated C57BL/6 recipients (given two doses of 4.5 Gy). At 6-8 weeks after reconstitution, mice were given three doses of tamoxifen (Sigma-Aldrich, St Louis, MO; 1 mg in sunflower oil with 10% ethanol per dose) intraperitoneally (i.p.). Mice were closely monitored and weighed daily. At the onset of weight loss (3-6 days after initial tamoxifen dose) mice were culled and samples taken for analyses. Mixed bone marrow chimeric mice were allocated to experimental groups based on genotype of the transplanted bone marrow. Where multiple groups of the same genotype were required, these were allocated randomly to the particular treatment conditions.
In Vivo Cytokine Neutralization
For in vivo neutralization of cytokines, mixed bone marrow chimeric mice (described above) were injected i.v. with antibodies two to four hours before tamoxifen injection. Chimeric mice were injected with 1 mg/mouse InVivoMab anti-mouse TNF (clone XT3.11, BE0058, BioXcell, West Lebanon, NH), 1 mg/mouse InVivoMab anti-mouse IL-6 (clone MP5-20F3, BE0046, BioXCell), 250 mg/mouse anti-mouse G-CSF (clone 67604, MAB414, R&D Systems), or the equivalent amount of InVivoMab Rat IgG1 isotype control (clone HRPN, BE0088, BioXCell). Mixed bone marrow chimeric mice were allocated to the experimental groups based on genotype of the transplanted bone marrow. Where multiple groups of the same genotype were required, these were allocated randomly to the particular treatment conditions. Cytokine/Chemokine, Autoantibody, and Immunoglobulin Analysis Cytokine/chemokine multiplex analysis was carried out using Luminex xMAP technology. Serum and medium samples were analyzed using magnetic MILLIPLEX MAP antibody-conjugated beads (Merck-Millipore, Bedford, MA) according to the manufacturer's instructions on a Luminex MAGPIX instrument with the xPONENT 4.2 software. For some G-CSF measurements, samples were diluted 1/10. For cytokine measurements from BMDMs, cells were split and equal numbers were reseeded in fresh medium
Circular Dichroism Experiments
Circular dichroism (CD) measurements were performed on a Jasco-J815 spectropolarimeter (Jasco International Co. Ltd., Tokyo, Japan), using a spectral band width of 1 nm and a cell path-length of 0.1 cm. OTULIN WT and OTULIN L272P were re-buffered in PBS at 0.38 mg/mL prior to the experiment. The far UV CD spectra were measured from 260-195 nm and were corrected for buffer contribution by baseline subtraction.
Nano-DSF Thermal Unfolding Experiments
Nano-DSF (differential scanning fluorimetry) measurements were performed using a Prometheus NT.48 instrument (NanoTemper Technologies GmbH, Germany). Experiments on OTULIN WT and OTULIN L272P were carried out at 0.11 mg/mL and 0.38 mg/mL (not shown). Samples were dialysed into PBS before measurement and 10 mL of each sample were loaded in UV capillaries (NanoTemper Technologies). Temperature gradient was set at 2.5 C/min in a range from 20 to 90 C. Protein unfolding was measured by detection of change in tryptophan fluorescence at emission wavelengths of 330 and 350 nm, dependent on temperature gradient. T m 's were calculated according to the manufacturer's instructions. Results were confirmed by differential scanning calorimetry and CD thermal melt experiments (data not shown).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as mean ± SEM unless otherwise indicated in figure legends. Sample number (n) indicates the number of independent biological samples in each experiment. Sample numbers and experimental repeats are indicated in figures and figure legends or methods section above. Data were analyzed using the two-sided nonparametric Mann-Whitney U test of the null hypothesis of continuous data unless otherwise indicated in figure legends or method details. Data analysis was not blinded. Differences in means were considered statistically significant at p < 0.05. Significance levels are: * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001; n.s., non-significant. Analyses were performed using the Graphpad Prism 6.0 software.
DATA AND SOFTWARE AVAILABILITY
Data Resources
Due to restrictions from the patient consent approved by the research ethics committee it is not be possible to deposit complete exome sequencing data in a public repository, but the data could be made available to interested researchers by contacting the authors. 
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